Biomarin Pharmaceutical Inc (BMRN): who owns it and who trades it
As of Nov 16, 2026, BMRN insiders reported 5 open-market sales worth $4.3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was George Eric Davis (Vice president), with $2.8M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Biomarin Pharmaceutical
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BMRN
562 funds and institutions reported BMRN shares worth $11.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 20.45M | 10.58% | $1.2B | +3% |
| Dodge & Cox | 14.84M | 7.68% | $849M | +2% |
| Primecap Management Co | 14.19M | 7.34% | $812M | No change |
| Vanguard Capital Management LLC | 8.74M | 4.52% | $500M | +1% |
| Vanguard Portfolio Management LLC | 8.65M | 4.47% | $495M | +4% |
| Norges Bank | 8.21M | 4.25% | $470M | – |
| State Street Corp | 7.80M | 4.04% | $446M | +7% |
| Viking Global Investors LP | 7.62M | 3.94% | $436M | +8% |
| Vestal Point Capital, LP | 6.03M | 3.12% | $345M | +69% |
| AQR Capital Management LLC | 5.70M | 2.95% | $323M | -26% |
| FMR LLC (Fidelity) | 4.82M | 2.50% | $276M | +35% |
| Dimensional Fund Advisors LP | 4.08M | 2.11% | $233M | +7% |
| Geode Capital Management, LLC | 3.91M | 2.02% | $224M | +2% |
| Assenagon Asset Management S.A. | 3.52M | 1.82% | $202M | +83% |
| Capital Research Global Investors | 3.50M | 1.81% | $201M | +0% |
| Deep Track Capital, LP | 3.31M | 1.71% | $189M | +188% |
| Millennium Management LLC | 2.07M | 1.07% | $119M | -31% |
| Charles Schwab Investment Management Inc | 1.62M | 0.84% | $92.5M | +2% |
| Sixth Street Partners Management Company, L.P. | 1.62M | 0.84% | $92.5M | – |
| First Trust Advisors LP | 1.61M | 0.83% | $91.9M | -4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BMRN insiders reported $0 of open-market purchases and $4.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | George Eric Davis | Vice president | Sale | 17,557 | $66.28 | $1.2M | Form 4 |
| May 7, 2026 | Gregory R Friberg | Vice president | Sale | 3,281 | $53.85 | $177K | Form 4 |
| Mar 11, 2026 | Charles Greg Guyer | Vice president | Sale | 16,486 | $60.46 | $997K | Form 4 |
| Feb 26, 2026 | Gregory R Friberg | Vice president | Sale | 6,326 | $60.38 | $382K | Form 4 |
| Feb 26, 2026 | George Eric Davis | Vice president | Sale | 26,061 | $61.36 | $1.6M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| George Eric Davis | EVP, Chief Legal Officer | – | $2.8M | Sep 2, 2026 |
| Charles Greg Guyer | EVP, Chief Technical Officer | – | $997K | Mar 11, 2026 |
| Gregory R Friberg | EVP, Chief R&D Officer | – | $559K | May 7, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BMRN short interest
Moderate short interest. 7.3% of BMRN shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 24%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 14.12M BMRN shares were sold short, 7.3% of the shares outstanding, up 17.2% from the report before. At the average daily volume of 2.45M shares, buying them all back would take about 5.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 14.12M | 7.29% | +17% | 2.45M | 5.8 |
| Oct 15, 2026 | 12.05M | 6.23% | +5% | 2.46M | 4.9 |
| Sep 30, 2026 | 11.52M | 5.95% | +14% | 2.09M | 5.5 |
| Sep 15, 2026 | 10.08M | 5.21% | +2% | 1.82M | 5.5 |
| Aug 31, 2026 | 9.88M | 5.10% | -3% | 1.71M | 5.8 |
| Aug 14, 2026 | 10.20M | 5.27% | -18% | 2.77M | 3.7 |
| Jul 31, 2026 | 12.50M | 6.46% | -13% | 1.68M | 7.4 |
| Jul 15, 2026 | 14.32M | 7.41% | +3% | 1.41M | 10.2 |
| Jun 30, 2026 | 13.91M | 7.20% | +11% | 2.30M | 6.0 |
| Jun 15, 2026 | 12.52M | 6.48% | +8% | 2.07M | 6.1 |
| May 29, 2026 | 11.61M | 6.00% | +2% | 2.92M | 4.0 |
| May 15, 2026 | 11.36M | 5.88% | +5% | 2.10M | 5.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Biomarin Pharmaceutical company events
Biomarin Pharmaceutical filed 23 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Oct 6, 2026ResultsReleased financial results. Filing
- Sep 30, 2026AgreementBioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). Filing
- Sep 15, 2026AnnouncementBioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. Filing
- Sep 14, 2026LeadershipThe Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date). Filing
- Sep 1, 2026AnnouncementAs previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation, entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited liability… Filing
- Aug 31, 2026AgreementBioMarin Pharmaceutical Inc. entered into a binding term sheet with Ascendis Pharma A/S that sets forth the terms and conditions for a global settlement and license agreement that resolves all pending proceedings relating to the BioMarin Patent Rights (as defined below). Filing
- Aug 18, 2026AgreementBioMarin Pharmaceutical Inc., a Delaware corporation, entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ), (ii) each of the holders of shares of Alesta identified on Schedule… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 13, 2026AnnouncementAmended an earlier report. Made another announcement. Filing
- Jun 4, 2026LeadershipBioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting). Filing
- May 4, 2026ResultsReleased financial results. Filing
- Apr 27, 2026DealThe information set forth in the “Introductory Note” above is incorporated into this Item 2.01 by reference. Filing
- Apr 23, 2026AnnouncementAs previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin entered into an Agreement and Plan of Merger with Amicus Therapeutics, Inc., providing for the merger of Merger Sub with and into Amicus, with Amicus… Filing
- Mar 16, 2026AnnouncementBioMarin Pharmaceutical Inc. announced its decision to discontinue dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency following the occurrence of several slipped capital femoral epiphysis (SCFE) events in two ongoing… Filing
- Feb 23, 2026ResultsReleased financial results. Filing
- Feb 12, 2026AgreementBioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as… Filing
- Jan 29, 2026AnnouncementShared information with investors. Filing
- Jan 26, 2026AnnouncementSupplemental Information In connection with the Offering, BioMarin distributed a preliminary offering memorandum to prospective investors, which memorandum includes a description of risks related to the Acquisition. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 22, 2025AnnouncementBioMarin Pharmaceutical Inc. announced its decision to discontinue development of BMN 349, an oral therapeutic for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease. Filing
- Dec 19, 2025AgreementBioMarin Pharmaceutical Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Amicus Therapeutics, Inc., and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin, providing for the merger of Merger Sub with and into Amicus, with Amicus… Filing
- Dec 17, 2025LeadershipBioMarin Pharmaceutical Inc. (BioMarin) announced the appointment of Rashmi Ramchandani as BioMarin’s Vice President, Chief Accounting Officer, effective January 19, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Biomarin Pharmaceutical financials
Famous investors that hold BMRN
6 of the 50 well-known investors we track reported holding BMRN in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $430M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 7.17M | $430M | 1.3% | -6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.18M | $131M | 0.1% | +95% |
| Israel Englander · Millennium Management | Q3 2026 | 1.22M | $73.1M | 0.1% | -41% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 878,931 | $52.7M | 0.1% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 727,771 | $43.7M | 0.1% | +61% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 4,088 | $245K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BMRN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 4, 2026 | BlackRock, Inc. | 13G/A | 10.0% |
| Nov 4, 2026 | BlackRock, Inc. | 13G/A | 10.0% |
Questions about Biomarin Pharmaceutical Inc (BMRN) stock
Who owns the most BMRN stock?
The largest reported owner of Biomarin Pharmaceutical Inc (BMRN) is BlackRock, Inc., with 10.6% of the company. In total, 562 funds and institutions reported holding BMRN at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BMRN insiders buying or selling?
In the last 12 months, BMRN insiders reported no open-market purchases and 5 sales worth $4.3M. The latest trade was on Sep 2, 2026. See every trade.
What is the short interest in BMRN?
As of Oct 30, 2026, 14.12M BMRN shares were sold short, 7.3% of the shares outstanding, up 17.2% from the report before. At the average daily volume of 2.45M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.
Which famous investors hold BMRN?
6 of the 50 well-known investors we track reported BMRN in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Israel Englander. The largest position is worth $430M. See all holders.
Executive pay
Biomarin Pharmaceutical's chief executive was paid a total of $21.9M for the year ended Dec 31, 2025. In the last 12 months, Biomarin Pharmaceutical's executives and directors bought no stock on the open market and sold $4.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.